Results: In total, 374 samples from 282 patients were identified (140 men and 142 women). Pleural malignancy within 6 months of initial thoracentesis was diagnosed in 99 patients (35.1%). No differences were detected for sensitivity and NPV for diagnosis of pleural malignancy between any two quartiles (p > 0.05). Samples collected from women had a higher sensitivity for predicting pleural malignancy (p ‫؍‬ 0.0011), and those collected from nonsmokers had a slightly higher but not statistically significant sensitivity for predicting pleural malignancy (p ‫؍‬ 0.057). Samples collected from subjects with no history of malignancy had a significantly higher NPV than samples collected from subjects with a history of malignancy (p < 0.001). After adjusting for these demographic and medical history factors, the associations of the pleural fluid volume quartiles with sensitivity and NPV did not change.
M
alignancy is a common cause of pleural disease and pleural effusions encountered in the clinical setting. The diagnosis is based on the finding of malignant cells in pleural fluid by cytologic examination, or by analysis of pleural biopsy specimens. The questions that must follow are as follows: how often is the pleural fluid cytology result positive in a patient with a known pleural-based malignancy, and what volume of fluid must be removed from the pleural space in order to achieve a positive result?
Various studies of the accuracy of cytologic diagnosis of malignant pleural effusions have been reported to range from 40 to 87%. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] In a 1985 study, Prakash and Reiman 6 established a diagnosis of malignancy in 57.6% of cases on the first pleural fluid cytologic analysis, and in 58.5% on repeat
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thoracentesis and pleural fluid analysis. Sahn 10 suggested that cytology findings of pleural fluid were positive in 60% of malignancies. Bueno et al 12 achieved similar results with 52.3% of patients with malignancy having positive pleural fluid cytology findings.
Less well studied is the amount of pleural fluid that should be removed to diagnose pleural malignancy. Suggestions exist, but an actual answer to this question has not yet been determined. It is generally thought that larger volumes collected by thoracentesis will result in more accurate results. However, the more appealing alternative would be that the volume of pleural fluid aspirated is not a predictor of finding malignant cells when present. Sahn 10 stated in his 1985 article that approximately 75% of patients known to have carcinomatous pleurisy would have pleural effusions in the range of 500 to 2,000 mL of fluid, while 10% would present with effusions Ͻ 500 mL and 10% with massive effusions. Collection volumes for optimal diagnostic accuracy of several hundred milliliters, 13 100 mL, 6 no less than 250 mL, 14 and only 50 to 100 mL 15 have all been suggested. The purpose of this retrospective chart analysis was to determine whether the volume of pleural fluid truly would make a diagnostic impact in patients with suspected pleural-based malignancy.
Materials and Methods
Between October 1, 1998, and June 30, 1999, 282 patients (140 men and 142 women) who underwent diagnostic thoracentesis at Henry Ford Hospital, resulting in 374 pleural fluid samples, were retrospectively identified. Each pleural fluid sample was submitted fresh and unfixed, and the entire volume was centrifuged. All of the resulting sediment was used for cytologic processing using cytospin slide and cell block preparation techniques. Cytology results were categorized as positive, negative, or abnormal (including suspicious). All results except those that were positive for malignancy were considered negative for the purpose of this analysis.
Medical records were abstracted for patient demographics, volume of pleural fluid sampled, pathologic diagnosis, and clinical diagnosis. The presence of pleural malignancy diagnosed by cytology or pleural biopsy at 6 months served as the "gold standard" for clinical diagnosis.
Samples were classified into quartiles based on volume of pleural fluid collected (ie, four levels with approximately equal numbers in each). Sensitivity and negative predictive value (NPV) for diagnosis of pleural malignancy were calculated within each quartile. Since no samples were classified as false-positive, the specificity and positive predictive value for each quartile were all 100%. No further analyses were done for these two measures.
Logistic regression models using generalized estimating equations (GEE) methods were done to compare the sensitivities and NPV among the four quartiles. GEE methods were chosen over standard logistic regression methods because of the nature of the data being analyzed. For standard logistic regression methods, one of the assumptions is that there is only one observation per individual included in the analysis. In this study, multiple samples could have been obtained from the same individual over the study period, and it was desirable to be able to use all information. GEE methods allow for multiple observations from an individual by modeling the potential correlation and variability among these observations.
Additionally, the effect of other demographic and medical history factors on the sensitivity and NPVs for diagnosis of pleural malignancy was assessed. The factors included sex, race (black vs nonblack), age (age Ͻ 70 years vs age Ն 70 years), smoking history (yes vs no), and personal history of any malignancy (yes vs no). Information on family history of lung cancer and radiation and asbestos exposure was collected, but it was not included in the analysis because of the small number of subjects with these documented factors. Logistic regression models, using GEE methods, were done to assess the effect of these factors on sensitivity and NPV.
Results
The average age of our population was 65.4 Ϯ 15.7 years. Risk factors for malignancy included tobacco abuse in 59.2% (167 of 282 patients), with an average (mean Ϯ SD) of 25.3 Ϯ 29.6 pack-years; a family history of lung cancer in 3.9% (11 of 282 patients); radiation exposure in 1.4% (4 of 282 patients); asbestos exposure in 3.2% (9 of 282 patients); and personal history of any malignancy in 36.9% (104 of 282 patients). A pleural malignancy was diagnosed in 99 patients (35.1%) within 6 months of thoracentesis, and a total of 132 samples were collected. The final diagnosis in patients with malignancy of the pleural space included lung adenocarcinoma in 18.2% (18 of 99 patients), small cell lung carcinoma in 7.1% (7 of 99 patients), squamous cell lung carcinoma in 6.1% (6 of 99 patients), malignant mesothelioma in 4.0% (4 of 99 patients), other nonspecified lung carcinoma in 16.2% (16 of 99 patients), and metastatic carcinoma in 48.5% (49 of 99 patients).
The 374 samples were classified into quartiles based on the pleural fluid volume. Table 1 contains the mean pleural fluid volume along with SD, range, and resulting sample sizes for each quartile. The sample sizes in the quartiles were not exactly equal because samples with the same pleural fluid volume were grouped together in the same quartile. The sensitivities for each pleural fluid volume quartile, as well as the demographic and medical history characteristics of interest, are given in Table 2. Table 2 also contains the p values from the logistic regression models, using GEE methods. No differences were detected between any two quartiles (p Ͼ 0.05). Samples collected from nonsmokers had a slightly higher, but not statistically significant, sensitivity than samples collected from smokers (70.3% vs 56%, p ϭ 0.057). However, samples collected from women had a higher sensitivity for predicting pleural malignancy than samples collected from men (67.5% vs 37.7%, p ϭ 0.0011). This gender difference in sensitivities did not affect the sensitivity differences in the pleural fluid volume quartiles: 1 vs 2, Additional analyses were done to assess a linear relationship of the actual pleural fluid volume on sensitivity. The relationship was in the positive direction, implying that sensitivity increased with volume. However, this positive relationship was not statistically significant (p ϭ 0.193, GEE logistic regression). Even after adjusting for gender, this relationship was not significant (p ϭ 0.060, GEE logistic regression).
The NPVs for each pleural fluid volume quartile, as well as the demographic and medical history characteristics of interest, are given in Table 3 . The differences between quartile 4 and quartiles 1 and 2 showed a slight, but not statistically significant, trend (p ϭ 0.099 and p ϭ 0.079, respectively). Samples collected from subjects with no history of malignancy have a significantly higher NPV than samples collected from subjects with a history of malignancy (91.4% vs 59.8%, p Ͻ 0.001). After adjusting for history of malignancy, the only difference in the quartiles that continued to show a slight trend was between quartiles 2 and 4 (p ϭ 0.056). No other quartile differences were observed after adjusting for history of malignancy: 1 vs 2, p ϭ 0.351; 1 vs 3, p ϭ 0.892; 1 vs 4, p ϭ 0.287; 2 vs 3, p ϭ 0.290; and 3 vs 4, p ϭ 0.298. Additional analyses were done to assess a linear relationship of the actual pleural fluid volume on NPV. This relationship was in the negative direction, implying that NPV decreased with increasing volume. This relationship showed a slight but not statistically significant trend (p ϭ 0.095, GEE logistic regression). This relationship was still not significant after adjusting for history of malignancy (p ϭ 0.193, GEE logistic regression).
Discussion
Many variables have been associated with the ability to find malignant cells in pleural fluid among patients who have a malignancy. Not all pleural effusions in patients with malignancy are caused by tumor implants in the pleura or pleural infiltration by malignancy. 10 Other causes of these paramalignant effusions include impaired pleural space lymphatic drainage because the mediastinal lymph nodes are infiltrated by tumor, bronchial obstruction that causes pneumonia or atelectasis, and pulmonary thromboembolic disease. However, when the pleura itself contains pleural implants or tumor infiltrates the pleura, a pleural effusion is typically seen. With primary lung cancer, a malignant pleural effusion is a sign of inoperability. For malignant mesothelioma and primary tumors from other organ sites that metastasize to the pleura, the finding of malignant cells in pleural fluid typically means that the patient has a limited life expectancy. The type of tumor that causes a pleural effusion affects the likelihood of finding malignant cells when pleural fluid is processed by cytology techniques. Squamous cell carcinoma more commonly causes a pleural effusion by bronchial obstruction or blockade of the lymphatic drainage than it causes direct implants or infiltrates in the pleura. 1, 5, 16 NonHodgkin lymphoma with pleural effusions was positive on cytologic analysis in 75% of patients in one series, in contrast with 25% for Hodgkin lymphoma with pleural effusions in another. 17 Adenocarcinoma involving the pleura is more frequently positive on cytology than sarcoma. 18 Carcinoma that arises in the breast and metastasizes to the pleura is more likely to be associated with a positive pleural fluid cytology specimen than is carcinoma of the lung. 6 Processing pleural fluid more than one way in the cytology laboratory (cell blocks and smears) is associated with more frequent identification of malignant cells than by either method alone. 7 Our data confirm this observation; of the 57 positive specimens that were reported separately for both methods of processing, 6 specimens were positive only by cell block technique, another 7 specimens were positive only by cytospin, while 44 specimens were positive by both methods of processing the pleural fluid specimens. Repeat thoracentesis with examination of two or three separate specimens is associated with an increased ability to recognize malignant cells. 5, 17 Pleural fluid cytology is more sensitive for the diagnosis of pleural malignancy than closed-needle pleural biopsy. 6 Adding closed-needle biopsy to pleural fluid cytology provides a modest incremental yield for the diagnosis of malignancy as compared with pleural fluid cytology alone. 1, 6, 8, 9, 12 Despite all these observations, few data are available to guide the clinician about the volume of pleural fluid that is needed to optimize the yield when there is clear-cut involvement of the pleura by the malignancy itself. Bueno et al 12 routinely submitted only 10 mL of pleural fluid for cytology, but diagnostic accuracy was 56% (true-positive). This is similar to the 57.6% yield reported by Prakash and Reiman, 6 who state that the optimal volume of fluid for cytologic preparations in their experience is 100 mL. They also state that a minimum of 2 to 3 mL of fluid has often been successful to diagnose malignant cells in pleural fluid. Spriggs and Boddington 16 recommend that anywhere from 10 to 20 mL should be submitted for cytologic processing. Leff et al 14 state that samples containing Ͻ 250 mL of pleural fluid often contain too few cells for adequate diagnosis of malignancy. Sahn 11 recommends that several hundred milliliters of fluid should be removed at the initial thoracentesis when the clinician suspects malignancy. In a position paper, the Health and Public Policy Committee of the American College of Physicians state that usually only 50 to 100 mL of fluid is required for diagnostic studies, but they do not speak directly to the issue of cytologic study for malignant cells. 15 In none of these reports are data provided to substantiate the recommended volume.
In our study it appears that, if malignant cells are present, they are equally likely to be identified on cytologic processing of small volumes of pleural fluid as with larger volumes. Our data support the conclusion that the sensitivity of pleural fluid analysis for the diagnosis of pleural-based malignancy is not dependent on the volume of pleural fluid extracted during diagnostic thoracentesis. There may be other reasons to remove large volumes of pleural fluid when effusions are massive, such as an attempt to relieve dyspnea or allow better radiographic display of the underlying lung after large volume thoracentesis. Complications such as pain after the procedure, pneumothorax, or re-expansion pulmonary edema may be more likely following removal of a very large volume of pleural fluid.
There are several limitations to this study. This review was a chart review retrospective analysis. Also, several patients had more than one pleural fluid sample sent from multiple thoracentesis procedures. We attempted to correct for this phenomenon by adjusting for this factor with the statistical analyses that were performed. In addition, we do not have an explanation for the observation that the sensitivity of pleural fluid analysis was statistically greater in women. Logistic regression models using GEE with correction for primary carcinoma of the female breast did not account for this observation. Despite these criticisms, the data available do suggest that cytologic processing of a small volume of pleural fluid may be as good as larger volumes for the diagnosis of pleural malignancy. It is possible that a larger prospective study may uncover a cut-point at a higher volume whereby sensitivity could be increased; however, it was not possible in this analysis.
Conclusion
The notion that large volumes of pleural fluid are needed to diagnose pleural malignancy is not supported by statistical data. We determined that diagnosis of malignancy is not dependent on the volume of pleural fluid sampled. Small volumes of pleural fluid can be used to accurately diagnose pleural malignancies with the same sensitivity and statistical accuracy as larger volumes of pleural fluid.
